Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-25
    E.g., 2018-06-25


19310 items
12:54 PM, May 25, 2018  |  BioCentury | Emerging Company Profile

Universal ambitions

Emergex Vaccines Holdings Ltd. is making synthetic peptide vaccines it thinks could provide universal immunity -- and at a fraction of the time and cost of traditional vaccine development. Emergex launched in 2016 with IP acquired...
11:05 AM, May 25, 2018  |  BioCentury | Finance

HKEX’s on-demand experts

The Hong Kong stock exchange is well aware its investor base is new to the high-risk, high-reward nature of its newly hatched biotech chapter and has no qualms about admitting its own lack of expertise....
10:40 AM, May 25, 2018  |  BioCentury | Finance

Grail’s Asia incentives

In light of Grail Inc.’s $300 million series C round from Chinese investors, the cancer detection company has several reasons to pursue a Hong Kong listing that go beyond high valuations. The series C round,...
6:09 AM, May 25, 2018  |  BioCentury | Regulation

Model alliance

An FDA pilot program on model-informed drug development could generate the information FDA needs to fulfill a commitment under PDUFA VI and answer a big industry ask: more clarity on the agency’s standards for accepting...
6:01 AM, May 25, 2018  |  BioCentury | Product Development

Patients at the core

With excitement mounting for the seven hemophilia gene therapies in the clinic, the National Hemophilia Foundation wanted to avoid a scenario in which patients, physicians and payers had no good way to compare them. The foundation...
5:04 AM, May 24, 2018  |  BioCentury | Finance

Chasing China

While Nan Fung Life Sciences had planned to establish a longer track record in biotech investments before launching its first China-focused fund, the group accelerated its plans to capitalize on the growing Chinese biotech industry....
5:03 PM, May 18, 2018  |  BioCentury | Politics, Policy & Law

Shifting parts

HHS Secretary Alex Azar is convinced that the way Medicare Part B spends money for drugs makes no sense, costs the taxpayers too much and isn’t good for patients. He says he’s open to suggestions...
2:15 PM, May 18, 2018  |  BioCentury | Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of investors...
1:40 PM, May 18, 2018  |  BioCentury | Finance

CellCentric’s magic trio

Five years after pivoting from target discovery to drug development, epigenetics play CellCentric Ltd. is taking its sole asset CCS1477 into the clinic next month with $26 million from Morningside Venture Investments. The company believes...
1:06 PM, May 18, 2018  |  BioCentury | Finance

Ansun’s China ambitions

The China-heavy syndicate behind Ansun BioPharma Inc.’s $85 million series A round reflects the San Diego-based antiviral company’s long-term plans to penetrate the China market. Sinopharm Healthcare Fund and Lilly Asia Ventures led the round, with...